A Phase 1 interventional study of ZN-c3 and Encorafenib in Metastatic Colorectal Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. Terminated at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 461 studies in Colorectal Neoplasms with a site in Spain — 96 open to participants now, 149 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.
Among the 461 studies in Colorectal Neoplasms with a site in Spain, this one is the 341st largest by enrollment of the 404 interventional ones that give a count, is one of 30 that started in 2023, is one of 79 in phase 1, and was the 355th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →96 of the 461 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
AbbVie · Sites in Spain, United States, Belgium and 7 more countries
Ages 18+
Gilead Sciences · Sites in Spain, United States, Australia and 1 more country
Ages 18+
Fundacion Clinic per a la Recerca Biomédica · Sites in Spain
Ages 50–69
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
461 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 146 · Phase 2 191 · Phase 3 73 · Phase 4 7
First in 1993; this study’s year is marked. 30 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 168 across the 404 interventional studies, 408 across the 54 observational. Of the 281 that completed or were terminated, 125 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
299 of 461 have an industry lead sponsor. The 10 most frequent:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Colorectal Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05988645MiWEndo Solutions S.L.Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | 2026-11-29 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 461 studies in Colorectal Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive different doses of ZN-c3 in combination with different doses of Encorafenib and a fixed dose of Cetuximab
Drug: ZN-c3 · Drug: Encorafenib · Drug: Cetuximab
Participants will receive recommended dose of ZN-c3 and encorafenib as determined in dose escalation phase in combination with cetuximab
Drug: ZN-c3 · Drug: Encorafenib · Drug: Cetuximab
ZN-c3 tablet by mouth, in combination with encorafenib
Encorafenib capsule by mouth, in combination with ZN-c3
Also known as: BRAFTOVI®
Infusion
Also known as: ERBITUX®
Dose Escalation Phase - Incidence of Dose Limiting Toxicities (DLTs)
DLTs defined as treatment-related AEs occurring within the first 29 days after the start of any study treatment that in the opinion of the investigator cannot be reasonably attributed to the participant's underlying disease, concomitant medications, or pre-existing conditions.
Time frame: From Lead-in Day -1 to Cycle 1 Day 28
Dose Expansion Phase - Objective response rate (ORR)
ORR defined as the proportion of participants who achieves a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator per RECIST Version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation Phase - Incidence and severity of adverse events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with dose interruptions due to AEs in Dose Escalation Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with dose modifications due to AEs in Dose Escalation Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with discontinuations due to AEs in Dose Escalation Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Dose Escalation Phase - Objective response rate (ORR)
ORR defined as the proportion of participants who achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) per RECIST Version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation Phase - Duration of Response (DOR)
DOR defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation Phase - Progression Free Survival (PFS)
PFS defined as the time from the first dose to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation Phase - Disease Control Rate (DCR)
DCR defined as the proportion of participants with BOR of CR, PR, or stable disease (SD), per RECIST version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation Phase - Time to Response (TTR)
TTR defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Escalation - ZN-c3 plasma exposure: AUC
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Escalation - ZN-c3 plasma exposure: Cmax
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Escalation - ZN-c3 plasma exposure: Tmax
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Escalation - Encorafenib plasma exposure: AUC
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Escalation - Encorafenib plasma exposure: Cmax
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Escalation - Encorafenib plasma exposure: Tmax
Time frame: From lead in day -1 visit through Cycle 1 Day 15
Dose Expansion Phase - Duration of Response (DOR)
DOR defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Expansion Phase - Progression Free Survival (PFS)
PFS defined as the time from the first dose to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Expansion Phase - Disease Control Rate (DCR)
DCR defined as the proportion of participants with BOR of CR, PR, or stable disease (SD), per RECIST version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Expansion Phase - Time to Response (TTR)
TTR defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST version 1.1.
Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Dose Expansion Phase - Incidence and severity of adverse events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with dose interruptions due to AEs in Dose Expansion Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with dose modifications due to AEs in Dose Expansion Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Proportion of participants with discontinuations due to AEs in Dose Expansion Phase
Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention
Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: AUC
Time frame: Lead in day 7
Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: Cmax
Time frame: Lead in day 7
Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: Tmax
Time frame: Day 7
Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: AUC
Time frame: Cycle 1 Day 15
Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: Cmax
Time frame: Cycle 1 Day 15
Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: Tmax
Time frame: Cycle 1 Day 15
Dose Expansion - ZN-c3 plasma exposure: AUC
Time frame: Cycle 1 Day 15
Dose Expansion - ZN-c3 plasma exposure: Cmax
Time frame: Cycle 1 Day 15
Tumor tissue BRAF V600E mutational status
Time frame: From lead in day 1 visit through the last dose of any study intervention, up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Jul 2024, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc